Ironwood Pharmaceuticals reported $57.33M in Operating Expenses for its fiscal quarter ending in December of 2024.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 270.57M 450K Sep/2026
Agios Pharmaceuticals USD 155.3M 24.53M Jun/2026
Akebia Therapeutics USD 63.08M 8.26M Dec/2025
Almirall EUR 531.16M 13.76M Jun/2026
Alnylam Pharmaceuticals USD 1.11B 52.78M Sep/2026
Amarin USD 51.48M 113K Dec/2025
Ardelyx USD 133.3M 6.04M Jun/2026
Astellas Pharma JPY 497.36B 41.8B Sep/2026
AstraZeneca USD 11.55B 674M Sep/2026
Charles River Laboratories USD 3.23B 387.38M Sep/2026
Coherus Biosciences USD 51.83M 2.48M Dec/2025
Emergent BioSolutions USD 555.9M 242.7M Jun/2023
Halozyme Therapeutics USD 198M 4.66M Sep/2026
Incyte USD 5.64B 4.67B Sep/2026
Ironwood Pharmaceuticals USD 57.33M 8.63M Dec/2024
Karyopharm Therapeutics USD 61.83M 9.9M Mar/2026
Lexicon Pharmaceuticals USD 20.27M 6.1M Dec/2025
MacroGenics USD 25.15M 17.72M Sep/2026
Moderna USD 1.18B 223M Sep/2026
Myriad Genetics USD 212.8M 16.2M Dec/2025
PTC Therapeutics USD 211.54M 15.12M Jun/2026
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Sarepta Therapeutics USD 390.39M 2.43M Sep/2026
Takeda JPY 981.78B 36.71B Sep/2026
Ultragenyx Pharmaceutical USD 283M 6M Sep/2026
Vanda Pharmaceuticals USD -1.14B 1.6B Dec/2025